HUP9802795A3 - Pharmaceutical compositions containing beta-adrenergic agent and anorectic agent for the treatment of corpulence - Google Patents

Pharmaceutical compositions containing beta-adrenergic agent and anorectic agent for the treatment of corpulence

Info

Publication number
HUP9802795A3
HUP9802795A3 HU9802795A HUP9802795A HUP9802795A3 HU P9802795 A3 HUP9802795 A3 HU P9802795A3 HU 9802795 A HU9802795 A HU 9802795A HU P9802795 A HUP9802795 A HU P9802795A HU P9802795 A3 HUP9802795 A3 HU P9802795A3
Authority
HU
Hungary
Prior art keywords
agent
corpulence
treatment
pharmaceutical compositions
compositions containing
Prior art date
Application number
HU9802795A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of HU9802795D0 publication Critical patent/HU9802795D0/hu
Publication of HUP9802795A2 publication Critical patent/HUP9802795A2/hu
Publication of HUP9802795A3 publication Critical patent/HUP9802795A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU9802795A 1997-12-03 1998-12-02 Pharmaceutical compositions containing beta-adrenergic agent and anorectic agent for the treatment of corpulence HUP9802795A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6726897P 1997-12-03 1997-12-03

Publications (3)

Publication Number Publication Date
HU9802795D0 HU9802795D0 (en) 1999-01-28
HUP9802795A2 HUP9802795A2 (hu) 1999-08-30
HUP9802795A3 true HUP9802795A3 (en) 2000-01-28

Family

ID=22074866

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9802795A HUP9802795A3 (en) 1997-12-03 1998-12-02 Pharmaceutical compositions containing beta-adrenergic agent and anorectic agent for the treatment of corpulence

Country Status (7)

Country Link
EP (1) EP0920864A1 (hu)
JP (1) JPH11228447A (hu)
KR (1) KR19990062718A (hu)
AU (1) AU9605598A (hu)
CA (1) CA2255318A1 (hu)
HU (1) HUP9802795A3 (hu)
IL (1) IL127306A0 (hu)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0858340A4 (en) * 1995-11-01 1999-12-29 Merck & Co Inc COMBINATION THERAPY FOR TREATING DIABETES AND OBESITY
US6246876B1 (en) 1997-11-13 2001-06-12 Telefonaktiebolaget L M Ericsson (Publ) Synchronization messages for hand-off operations
US6090942A (en) * 1998-10-15 2000-07-18 Pfizer Inc. Process and intermediates for a β3 -adrenergic receptor agonist
KR20010102198A (ko) 1999-02-16 2001-11-15 후루타 타케시 치환 아세틸피리딘 유도체 및 그를 이용하는 광학활성 β3작용제 중간체의 제조 방법
US6344481B1 (en) * 1999-03-01 2002-02-05 Pfizer Inc. Thyromimetic antiobesity agents
WO2001021577A2 (en) * 1999-09-20 2001-03-29 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
FR2814678B1 (fr) † 2000-10-04 2002-12-20 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
NZ532427A (en) 2001-09-24 2008-07-31 Imp Innovations Ltd Modification of feeding behavior using PYY (peptide YY) and its agonists such as NPY (neuropeptide Y)
CA2472882A1 (en) * 2002-01-10 2003-07-17 Imperial College Innovations Ltd Use of pyy and glp-1, or an agonist thereof, for the modification of feeding behaviour
US8058233B2 (en) 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
EP1496838B1 (en) 2002-03-12 2010-11-03 Merck Sharp & Dohme Corp. Substituted amides
GB0300571D0 (en) * 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
BRPI0620386A2 (pt) * 2005-12-21 2011-12-20 Schering Corp composição compreendendo a combinação de um antagonista de h3/agonista inverso e um supressor de apetite e uso da referida composição
JPWO2007139062A1 (ja) * 2006-05-30 2009-10-08 杏林製薬株式会社 肥満治療剤並びに肥満の治療及び予防方法
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
JP6253451B2 (ja) 2014-02-05 2017-12-27 学校法人自治医科大学 満腹感持続剤および満足感を維持する方法
AU2016379345B2 (en) 2015-12-22 2020-09-17 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
SG10202005916QA (en) 2015-12-22 2020-07-29 Zogenix International Ltd Fenfluramine compositions and methods of preparing the same
AU2017315273B2 (en) 2016-08-24 2021-04-29 Zogenix International Limited Formulation for inhibiting formation of 5-HT 2B agonists and methods of using same
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
EP3790537A1 (en) 2018-05-11 2021-03-17 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996035671A1 (en) * 1995-05-10 1996-11-14 Pfizer Inc. β-ADRENERGIC AGONISTS
WO1996035670A1 (en) * 1995-05-10 1996-11-14 Pfizer Inc. β-ADRENERGIC AGONISTS
EP0858340A4 (en) * 1995-11-01 1999-12-29 Merck & Co Inc COMBINATION THERAPY FOR TREATING DIABETES AND OBESITY

Also Published As

Publication number Publication date
AU9605598A (en) 1999-06-24
HU9802795D0 (en) 1999-01-28
KR19990062718A (ko) 1999-07-26
CA2255318A1 (en) 1999-06-03
EP0920864A1 (en) 1999-06-09
HUP9802795A2 (hu) 1999-08-30
IL127306A0 (en) 1999-09-22
JPH11228447A (ja) 1999-08-24

Similar Documents

Publication Publication Date Title
HUP9802795A3 (en) Pharmaceutical compositions containing beta-adrenergic agent and anorectic agent for the treatment of corpulence
IL147217A0 (en) New spirooxindole derivatives and pharmaceutical compositions containing the same for treatment of pain
NZ513889A (en) Kappa agonist compounds, pharmaceutical formulations and methods of prevention and treatment of pruritus therewith
HK1029914A1 (en) Device and pharmaceutical agent for treatment of dysmenorrhea
IL127189A0 (en) Compositions methods and devices for the transdermal delivery of drugs
IL114586A (en) Droloxifene for use in the treatment of cardiovascular diseases and pharmaceutical compositions comprising same
ZA968907B (en) Compositions and methods for buccal delivery of pharmaceutical agents
HK1022835A1 (en) Pharmaceutical composition for treatment of diabetes
HUP0103856A3 (en) Pharmaceutical composition for the treatment of acute disorders
IL133420A0 (en) Pharmaceutical composition for combination of piperidinoalkanol-decongestant
AUPO727097A0 (en) Method of treatment of hepatoma and pharmaceutical compositions for use therein
GB0015235D0 (en) Compositions for the treatment of skin and anorectal conditions
HUP0104696A3 (en) Pharmaceutical composition containing 5ht1 receptor agonists and metoclopramide for the treatment of migraine
PL316528A1 (en) Pharmaceutic compositions and drugs for prevetion and treatment of endothelial disorders
GB2311940B (en) Pharmaceutical compositions for the treatment of rhinitis
IL138888A0 (en) Pharmaceutical composition and combination preparation for immunosuppressive therapy
HUP0001858A3 (en) Bi-aromatic compounds and pharmaceutical and cosmetic compositions containing same and the use of the compounds
HUP0003679A3 (en) Use of pkc inhibitors for the preparation of pharmaceutical compositions treating cardiovascular diseases
GB2331926B (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
HUP0003097A3 (en) Use of intravenous contrast agents and devices for projection mammography
HUP0101733A3 (en) Pharmaceutical compositions containing sulfonyl-dipeptides and their use
IL121329A (en) Pharmaceutical composition for the treatment of cancer comprising somatostatin2 and other peptides
HUP0003074A3 (en) Pharmaceutical composition comprising ssri and betha-blocking agent
EP0981357A4 (en) METHODS AND COMPOSITIONS APPLICABLE TO THE DIAGNOSIS AND TREATMENT OF NEUROPSYCHIATRIC DISORDERS
HU0500865D0 (en) Use of teophyllin derivatives for the preparation of pharmaceutical compositions for the prevention and treatment of shock